Related Experiment Video

Updated: Aug 24, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Antisense approaches in prostate cancer

Kim N Chi1, Martin E Gleave

  • 1BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada. kchi@bccancer.bc.ca

Expert Opinion on Biological Therapy
|June 4, 2004
PubMed

Insights

Antisense oligonucleotides offer a promising new therapy for hormone refractory prostate cancer by targeting specific genes involved in cancer progression. This approach is particularly useful when other treatments are ineffective.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hormone refractory prostate cancer lacks effective treatment options, necessitating novel therapeutic strategies.
  • Understanding molecular pathways driving prostate cancer progression has revealed numerous gene targets.
  • Antisense oligonucleotides (ASOs) represent a targeted gene inhibition technology.

Purpose of the Study:

  • To review the current status and future potential of antisense oligonucleotides for prostate cancer therapy.
  • To identify key gene targets amenable to antisense oligonucleotide intervention in prostate cancer.

Main Methods:

  • Review of scientific literature on antisense oligonucleotides and prostate cancer molecular targets.
  • Analysis of genes implicated in prostate cancer progression, including apoptosis, growth factors, cell signaling, and androgen receptor (AR).

Main Results:

  • ASOs can specifically inhibit gene expression by binding to complementary mRNA.
  • Several gene targets, including BCL-2, clusterin, IAP family, MDM2, and AR, are being investigated for ASO therapy.
  • ASO therapy shows promise for genes whose products are not targeted by small molecules or antibodies.

Conclusions:

  • Antisense oligonucleotides hold significant therapeutic promise for hormone refractory prostate cancer.
  • Targeting specific genes involved in cancer progression offers a viable treatment modality.
  • Further research and clinical development of ASOs are warranted for prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...